January News

January 17, 2023

Department Updates

• Dr. Kathy Steece-Collier has been involved with MSU’s Spartan Innovation to form a new company called CavGene Therapeutics, Inc. CavGene Therapeutics, Inc. is a startup gene therapy company focused on therapeutics for neurodegenerative disease, with the first goal to develop a humanized tag-free CaV1.3 sh/miRNA vector for the treatment of levodopa-induced dyskinesia and concomitant therapeutic motor benefit. 
• TransNeuro’s (Vega, Lipton) application for CHM’s 1964 Project funds to develop a neuro-focused cluster (in the Doug Meijer Medical Innovation Building) studying health disparities in Alzheimer’s and related dementias received the highest score in the competition. Secondary collaborative entities include the Center for Bioethics and Social Justice and the Charles Stewart Mott Department of Public Health. This will further extend TransNeuro’s work into health disparities research and grow collaborative opportunities for all faculty. 
• Dr. Dave Morgan was interviewed by WOOD TV about a new Alzheimer’s drug that has been approved by the FDA.